Vimarsana
Biggest News Aggregation in the World

Virtual Rd Day News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Virtual Rd Day. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Virtual Rd Day Today - Breaking & Trending Today

In Person & Virtual R&D Day: The Anti Fibrotic Effects of Setanaxib and TARPEYO's Mode of Action - Vimarsana News

In Person & Virtual R&D Day: The Anti Fibrotic Effects of Setanaxib and TARPEYO's Mode of Action

English ...

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q1 2023 Earnings Call Transcript - Vimarsana News

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q1 2023 Earnings Call Transcript

Operator: Thank you for standing by. This is the conference operator. Welcome to the Taysha Gene Therapies First Quarter 2023 Earnings Conference Call.

Poseida Therapeutics Hosts Third Annual Virtual R&D Day Highlighting Novel Pipeline Assets and Latest Technology Innovations - Vimarsana News

Poseida Therapeutics Hosts Third Annual Virtual R&D Day Highlighting Novel Pipeline Assets and Latest Technology Innovations

/PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with...

Trevi Therapeutics Announces Positive Data from Full Set of Subjects in Phase 2 CANAL Trial of Haduvio™ in the Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis - Vimarsana News

Trevi Therapeutics Announces Positive Data from Full Set of Subjects in Phase 2 CANAL Trial of Haduvio™ in the Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis

/PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy, Haduvio™ (oral...

Astria Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate Update - Vimarsana News

Astria Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate Update

-- FDA Cleared IND Application for STAR-0215 for the Treatment of Hereditary Angioedema ---- Phase 1a Clinical Trial of STAR-0215 in Healthy Subjects Initiated, Preliminary Results Anticipated by Year-End 2022 ---- Company to Host a Virtual R&D Day on September 30 --BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc....